SciClone Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 81   

Articles published

SCLN 8.85
price chart
Update: SciClone Pharmaceuticals Exceeds Earnings Estimates For Q3 (SCLN)
What matters is that sales of the company's leading product, Zadaxin increased 28.4% to $32.1 million year-over-year. This shows that demand for the drug has increased at a strong pace.
SciClone Pharmaceuticals Stock Rating Lowered by BWS Financial (SCLN)  Ticker Report
Related articles »  
SciClone Pharmaceuticals Inc. (SCLN) Hits New 52-week High During ...
SciClone Pharmaceuticals Inc. (SCLN) hit a new 52-week high yesterday, reaching a peak of $8.94 after opening at $8.68 and closing at $8.64 for a move of -1.03%.
Related articles »  
Aegis Reiterates $10.00 Price Target for SciClone Pharmaceuticals (NASDAQ ...
SciClone Pharmaceuticals, Inc. logo Aegis set a $10.00 price objective on SciClone Pharmaceuticals (NASDAQ:SCLN) in a research report released on Friday morning.
Related articles »  
Stock to Focus SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN)
[Market Wired] SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) (Trend Analysis) announced that Wilson W. Cheung, Chief Financial Officer, will present a corporate overview and business update at the Aegis Capital Corp.
Stock Insights on SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN)
[] SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) hit a new 52-week high, reaching a peak of $8.44 after opening at $8.03 and closing at $8.24 for a move of 1.73%.
BWS Financial Downgrades SciClone Pharmaceuticals to Hold (SCLN)  sleekmoney
Related articles »  
SciClone Pharmaceuticals PT Set at $10.00 by Aegis (NASDAQ:SCLN)
SciClone Pharmaceuticals (NASDAQ:SCLN) last posted its quarterly earnings results on Monday, November 10th. The company reported $0.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.12 by $0.05. The company had ...
SciClone Pharmaceuticals Director Sells $137201 in Stock (SCLN)
Shares of SciClone Pharmaceuticals (NASDAQ:SCLN) traded up 0.97% during mid-day trading on Monday, hitting $8.31. 62,732 shares of the company's stock traded hands. SciClone Pharmaceuticals has a 1-year low of $4.24 and a 1-year high of $9.00.
SciClone Pharmaceuticals' (SCLN) CEO Friedhelm Blobel on Q3 2014 Results ...
SciClone Pharmaceuticals' (SCLN) CEO Friedhelm Blobel on Q3 2014 Results - Earnings Call Transcript. Nov. 10, 2014 9:47 PM ET | About: SciClone Pharmaceuticals, Inc. (SCLN) by: SA Transcripts. SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN).
Related articles »  
Commit To Buy SciClone Pharmaceuticals At $7.50, Earn 15.5% Annualized ...
Investors eyeing a purchase of SciClone Pharmaceuticals, Inc. (Symbol: SCLN) shares, but tentative about paying the going market price of $8.30/share, might benefit from considering selling puts among the alternative strategies at their disposal.
SciClone Pharmaceuticals Sets New 1-Year High After Earnings Beat (SCLN)  WKRB News
Related articles »  
SciClone Pharmaceuticals, Inc. (SCLN): SciClone Pharmaceuticals rises ...
Q3 Zadaxin sales: $25M. That's +15% sequentially, but -20% Y/Y. CEO Friedhelm Blobel notes that while SCLN "expects to see continued growth through the remainder of the year, [the company] expects the rate of growth to continue to be affected by ...
Related articles »